BioWorld MedTech

Sep. 25, 2013

AdvaMed 2013: Market projected to achieve global sales of $455B in 2018

WASHINGTON — While 2013 has been a rough year for the med-tech market, a report from EvaluateMedTech forecasts happier days ahead, with the industry approaching $455 billion in global sales in 2018. Read More

AdvaMed 2013: Silverman; measures tough to come by for quality initiative

FDA revises Sapien labeling, expanding patient population

Solana launches FuseFORCE SuperElastic fixation system

Report from Europe: LabStyle gets CE mark for its Dario glucose monitor

Deals roundup: Greenway acquires Vitera in transaction for $644 million

Patent watch: HiberGene Diagnostics secures patent for Meningoccus test

People in Places

Financings roundup: Ventas reveals pricing of senior notes offering

Agreements/contracts: Piedmont Healthcare, Vanderbilt in pact to deploy CaseXpertSM

Product Briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 21, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...